Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use FABHALTA safely and effectively. See full prescribing information for FABHALTA. FABHALTA® (iptacopan) capsules, for oral use Initial U.S. Approval: 2023
Medication labelWhy this: Advisory · dailymed-prescription
FABHALTA is indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH). FABHALTA is indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression. FABHALTA is indicated for the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria.
- generic_name
- iptacopan
- product_names
- iptacopan
- ndc
- 0078-1189, 0078-1189-20
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en